Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John W Mellors

Showing results (1-10 of 331) with videos related to

Pageof 34
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 5, 2021
Improving the Outcomes of Immunocompromised Patients With Coronavirus Disease 2019Ghady Haidar, John W Mellors
Antiviral Therapy|May 2, 2022
The transformation of HIV therapy: One pill once a dayMadhu C Choudhary, John W Mellors
Current Opinion in HIV and AIDS|June 28, 2022
How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?Urvi M Parikh, John W Mellors
Current Opinion in HIV and AIDS|November 18, 2014
Changes in HIV reservoirs during long-term antiretroviral therapyFeiyu F Hong, John W Mellors
Current Opinion in HIV and AIDS|December 4, 2015
Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?Urvi M Parikh, John W Mellors
Current Opinion in Virology|March 18, 2016
Which therapeutic strategy will achieve a cure for HIV-1?Anthony R Cillo, John W Mellors
AIDS Reviews|June 3, 2015
Impact of Antiretroviral Therapy on HIV-1 Persistence: The Case for Early InitiationFeiyu F Hong, John W Mellors
Future Microbiology|August 24, 2012
Pretreatment HIV-1 drug resistance is strongly associated with virologic failure in HIV-infected patients receiving partly active antiretroviral regimensUrvi M Parikh, John W Mellors
Infectious Disease Clinics of North America|June 14, 2024
The Current Pipeline of Antiretroviral Therapy: Expanding Options and Filling GapsYijia Li, Madhu Choudhary, John W Mellors
Open Forum Infectious Diseases|May 30, 2019
Telemedicine and Infectious Diseases Practice: A Leap Forward or a Step Back?Rima C Abdel-Massih, John W Mellors
Pageof 34

Showing results (1-10 of 331) with videos related to

Sort By:
Pageof 34
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 5, 2021
Improving the Outcomes of Immunocompromised Patients With Coronavirus Disease 2019Ghady Haidar, John W Mellors
Antiviral Therapy|May 2, 2022
The transformation of HIV therapy: One pill once a dayMadhu C Choudhary, John W Mellors
Current Opinion in HIV and AIDS|June 28, 2022
How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?Urvi M Parikh, John W Mellors
Current Opinion in HIV and AIDS|November 18, 2014
Changes in HIV reservoirs during long-term antiretroviral therapyFeiyu F Hong, John W Mellors
Current Opinion in HIV and AIDS|December 4, 2015
Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?Urvi M Parikh, John W Mellors
Current Opinion in Virology|March 18, 2016
Which therapeutic strategy will achieve a cure for HIV-1?Anthony R Cillo, John W Mellors
AIDS Reviews|June 3, 2015
Impact of Antiretroviral Therapy on HIV-1 Persistence: The Case for Early InitiationFeiyu F Hong, John W Mellors
Future Microbiology|August 24, 2012
Pretreatment HIV-1 drug resistance is strongly associated with virologic failure in HIV-infected patients receiving partly active antiretroviral regimensUrvi M Parikh, John W Mellors
Infectious Disease Clinics of North America|June 14, 2024
The Current Pipeline of Antiretroviral Therapy: Expanding Options and Filling GapsYijia Li, Madhu Choudhary, John W Mellors
Open Forum Infectious Diseases|May 30, 2019
Telemedicine and Infectious Diseases Practice: A Leap Forward or a Step Back?Rima C Abdel-Massih, John W Mellors
Pageof 34